文献速递血液净化与透析水电解质与酸碱肾血管病与高血压

维持性血透患者继发性甲旁亢不同治疗策略比较:观察性试验模拟

Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation.
PubMed 文献 · Am J Kidney Dis · 2023-09-09

两项观察性临床试验模拟纳入全国透析机构成年血透患者,比较PTH目标策略与药物选择策略。PTH较低目标组较较高目标组全因死亡风险降低(HR 0.71),心血管住院风险降低(HR 0.78)。西那卡塞优先组较维生素D优先组死亡风险降低(HR 0.79),但心血管住院无显著差异。

要点

  • 较低PTH目标策略与全因死亡风险降低相关(HR 0.71)
  • 较低PTH目标策略与心血管住院风险降低相关(HR 0.78)
  • 西那卡塞优先组死亡风险低于维生素D优先组(HR 0.79)

核心结论

  • 以较低PTH为目标的SHPT管理可能降低维持性HD患者的死亡率和心血管疾病风险,需实用随机试验确认。

研究设计与样本

  • 两项观察性临床试验模拟,纳入全国透析机构接受中心HD的成人,2009-2014年期间有SHPT,Medicare为 primary payer 且保险≥180天,无禁忌或健康状况限制理论试验参与。

主要发现

  • PTH目标试验纳入1152例患者(较低目标组635例,较高目标组517例)。
  • 较低PTH目标组较较高目标组全因死亡风险降低(HR 0.71 [95% CI 0.52-0.93]),心血管住院风险降低(HR 0.78 [95% CI 0.63-0.98]),复合终点风险降低(HR 0.74 [95% CI 0.61-0.89])。
  • 药物试验纳入2726例独特患者共6727例患者试验(维生素D优先6268例,西那卡塞优先459例)。
  • 西那卡塞优先组较维生素D优先组全因死亡风险降低(HR 0.79 [95% CI 0.62-0.99]),心血管住院及复合终点无显著差异。

关键数值与推荐

  • PTH目标试验:新发SHPT(首次PTH 300-600 pg/mL),30天内上调维生素D甾醇或西那卡塞(较低目标)vs 不上调(较高目标)。
  • 药物试验:PTH≥300 pg/mL且每周维生素D甾醇≥6 μg(帕立骨化醇等效剂量)且无西那卡塞使用史,30天内首次剂量或药物改变定义维生素D优先(上调维生素D)vs 西那卡塞优先(加用西那卡塞)vs 未定义。
  • 主要结局为24个月全因死亡;次要结局包括心血管住院或心血管住院与死亡的复合终点。

临床怎么用

  • 原文建议这些发现需在实用随机试验中确认。

局限性

  • 存在残余混杂可能;西那卡塞使用率低且统计效能低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Optimal approaches to treat secondary hyperparathyroidism (SHPT) in patients on maintenance hemodialysis (HD) have yet to be established in randomized controlled trials (RCTs). STUDY DESIGN: Two observational clinical trial emulations. SETTING & PARTICIPANTS: Both emulations included adults receiving in-center HD from a national dialysis organization. The patients who had SHPT in the period between 2009 and 2014, were insured for≥180 days by Medicare as primary payer, and did not have contraindications or poor health status limiting theoretical trial participation. EXPOSURE: The parathyroid hormone (PTH) Target Trial emulation included patients with new-onset SHPT (first PTH 300-600pg/mL), with 2 arms defined as up-titration of either vitamin D sterols or cinacalcet within 30 days (lower target) or no up-titration (higher target). The Agent Trial emulation included patients with a PTH≥300 pg/mL while on≥6μg weekly of vitamin D sterol (paricalcitol equivalent dose) and no prior history of cinacalcet. The 2 arms were defined by the first dose or agent change within 30 days (vitamin D-favoring [vitamin-D was up-titrated] vs cinacalcet-favoring [cinacalcet was added] vs nondefined [neither applies]). Multiple trials per patient were allowed in trial 2. OUTCOME: The primary outcome was all-cause death over 24 months; secondary outcomes included cardiovascular (CV) hospitalization or the composite of CV hospitalization or death. ANALYTICAL APPROACH: Pooled logistic regression. RESULTS: There were 1,152 patients in the PTH Target Trial (635 lower target and 517 higher target). There were 2,726 unique patients with 6,727 patient trials in the Agent Trial (6,268 vitamin D-favoring trials and 459 cinacalcet-favoring trials). The lower PTH target approach was associated with reduced adjusted hazard of death (HR, 0.71 [95% CI, 0.52-0.93]), CV hospitalization (HR, 0.78 [95% CI, 0.63-0.98]), and their composite (HR, 0.74 [95% CI, 0.61-0.89]). The cinacalcet-favoring approach demonstrated lower adjusted hazard of death compared to the vitamin D-favoring approach (HR, 0.79 [95% CI, 0.62-0.99]), but not of CV hospitalization or the composite outcome. LIMITATIONS: Potential for residual confounding; low use of cinacalcet with low power. CONCLUSIONS: SHPT management that is focused on lower PTH targets may lower mortality and CV disease in patients receiving HD. These findings should be confirmed in a pragmatic randomized trial. PLAIN-LANGUAGE SUMMARY: Optimal approaches to treat secondary hyperparathyroidism (SHPT) have not been established in randomized controlled trials. Data from a national dialysis organization was used to identify patients with SHPT in whom escalated treatment may be indicated. The approach to treatment was defined based on observed upward titration of SHPT-controlling medications: earlier titration (lower target) versus delayed titration (higher target); and the choice of medication (cinacalcet vs vitamin D sterols). In the first trial emulation, we estimated a 29% lower rate of death and 26% lower rate of cardiovascular disease or death for patients managed with a lower versus higher target approach. Cinacalcet versus vitamin D-favoring approaches were not consistently associated with outcomes in the second trial emulation. This observational study suggests the need for additional clinical trials of SHPT treatment intensity.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Platt A, Wilson J, Hall R, et al. Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation. Am J Kidney Dis. 2023. PMID: 37690631. doi:10.1053/j.ajkd.2023.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。